Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison between 5 - azacytidine treatment and 5 - azacytidine followed by allogeneic stem cell transplantation in elderly patients with advanced MDS according to donor availability

Next Previous
Trial Profile

Comparison between 5 - azacytidine treatment and 5 - azacytidine followed by allogeneic stem cell transplantation in elderly patients with advanced MDS according to donor availability

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Allogeneic stem cell therapy; Amsacrine; Busulfan; Cytarabine; Fludarabine
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms VidazaAllo

Most Recent Events

  • 20 Jul 2021 Results (n=162) assessing efficacy and safety compared HSCT following 5-aza pretreatment with continuous 5-aza treatment in patients with higher-risk MDS age 55-70 years, published in the Journal of Clinical Oncology..
  • 21 Aug 2019 This trial has been completed in Germany according to European Clinical Trials Database record
  • 04 Dec 2018 Primary endpoint (overall survival) has been met, according to the results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top